NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
1 Year : From Feb 2019 to Feb 2020
Management to discuss new partner pharmacy program and expanded
access to in-office direct channel
Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing prescription
Avenova® for the domestic eye care market, announces that it
will report first quarter 2019 financial results after market close on
Thursday, May 9, 2019 and will hold an investment community conference
call that day.
In addition to discussing financial results during the call, management
will provide updates on recent initiatives to increase sales while
decreasing costs. The sales initiatives entail improved patient
accessibility to Avenova through an expanded partner pharmacy program
and increased outreach efforts to eye care specialists to sell Avenova
directly to their patients through its in-office direct channel.
Management will also provide an update on previously announced
cost-containment measures to align expenses with the recent strategic
shift in its commercialization strategy.
Thursday, May 9
4:30 p.m. ET / 1:30 p.m. PT
800-608-8202 from within the U.S.
702-495-1913 from outside the U.S.
Enter conference identification number 8495204
The live call also will be available at http://novabay.com/investors/events.
A replay of the call will be available beginning two hours after its
completion through 11:59 p.m. Pacific time May 17, 2019, by dialing
855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S.
and entering the conference identification number 8495204. The call will
also be archived at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on
commercializing and developing its non-antibiotic anti-infective
products to address the unmet therapeutic needs of the global, topical
anti-infective market with its two distinct product categories: the
NEUTROX® family of products and the AGANOCIDE®
compounds. The Neutrox family of products includes AVENOVA®
for the eye care market, NEUTROPHASE® for wound care market,
and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target applications
in the dermatology and urology markets.
Socialize and Stay informed on NovaBay’s
progress:Like us on FacebookFollow
us on TwitterConnect
with NovaBay on LinkedInJoin
us on Google+Visit
Avenova Purchasing InformationFor
NovaBay Avenova purchasing information:Please call 800-890-0329 or
View source version on businesswire.com: https://www.businesswire.com/news/home/20190430005264/en/
NovaBay ContactJustin HallInterim
President and Chief Executive Officer510firstname.lastname@example.org
Investor ContactLHA Investor